Brokerages Set Certara, Inc. (NASDAQ:CERT) PT at $15.67

Shares of Certara, Inc. (NASDAQ:CERT) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $15.67.

Several brokerages recently weighed in on CERT. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research note on Tuesday, May 6th. Robert W. Baird increased their target price on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. TD Cowen assumed coverage on shares of Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 target price on the stock. William Blair reissued a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Finally, Barclays upgraded shares of Certara from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $11.00 to $14.00 in a research note on Thursday, May 8th.

Certara Stock Up 1.6%

NASDAQ CERT opened at $12.18 on Friday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a 52 week low of $8.64 and a 52 week high of $16.93. The business’s fifty day simple moving average is $12.15 and its 200-day simple moving average is $11.87. The firm has a market cap of $1.98 billion, a PE ratio of -60.90, a P/E/G ratio of 9.29 and a beta of 1.44.

Certara (NASDAQ:CERT) last posted its earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 EPS. As a group, equities analysts anticipate that Certara will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Certara

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC grew its holdings in Certara by 17.1% in the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after purchasing an additional 40,463 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Certara by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after purchasing an additional 35,954 shares during the period. Goldman Sachs Group Inc. grew its holdings in Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after purchasing an additional 90,724 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Certara in the first quarter valued at approximately $297,000. Finally, Select Equity Group L.P. grew its holdings in Certara by 534.5% in the first quarter. Select Equity Group L.P. now owns 1,094,495 shares of the company’s stock valued at $10,836,000 after purchasing an additional 922,007 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.